Pembrolizumab Plus Chemo Improved Survival in Advanced NSCLC
In KEYNOTE-189, a pembrolizumab/chemo combination yielded OS and PFS benefits in patients with advanced NSCLC.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
SUBSCRIBE: Print / eNewsletter
Pembrolizumab Plus Chemo Improved Survival in Advanced NSCLCApr 24, 2018 In KEYNOTE-189, a pembrolizumab/chemo combination yielded OS and PFS benefits in patients with advanced NSCLC. |
Xenograft Platform Could Lead to Mouse-Based Clinical TrialsApr 24, 2018 In this video, Dr. Edison Liu describes a novel patient-derived xenograft platform that might enable development of a mouse-based clinical trials program. |
Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast CancerApr 23, 2018 A simple prognostic tool could be used to identify patients with HR-positive breast cancer who underwent 5 years of endocrine treatment and who might be at higher risk of late distant recurrence. |
Forecasting PARP Inhibitor Resistance in Breast Cancer PatientsApr 23, 2018 In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in ovarian cancer, and the importance of understanding how resistance to these agents develops. |
Late Diagnosis: Cause of Poorer Survival in Alcohol-Related Liver Cancer?Apr 23, 2018 Patients with alcohol-related HCC had worse OS than other HCC patients, mainly due to poorer liver function and more unfavorable tumor characteristics at diagnosis. |
Cancer Care Becoming More Patient-CentricApr 20, 2018 In this podcast, Dr. Debra Patt discusses trends in cancer care, including how treatments are becoming more personalized and less toxic. |
Prostate Cancer Screening in African-American MenApr 20, 2018 In this video, Dr. Judd Moul discusses disparities in prostate cancer screening among African-American men, and the need for more research in this area. |
TLR9 Agonist May Reverse Resistance to Immune Checkpoint Inhibition in MelanomaApr 20, 2018 Treatment with the TLR9 agonist CMP-001 appeared to potentially reverse resistance to immune checkpoint inhibition in patients with metastatic melanoma. |
Duvelisib Granted Priority Review for R/R CLL/SLL and FLApr 19, 2018 In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively. |
Venetoclax/Rituximab Found Superior to Chemotherapy in CLLApr 19, 2018 The combination of rituximab and the BCL2 inhibitor venetoclax significantly lengthened PFS among CLL patients in the phase III MURANO trial. |